EP3973296A1 - Verfahren zur herstellung einer peptidprobe - Google Patents

Verfahren zur herstellung einer peptidprobe

Info

Publication number
EP3973296A1
EP3973296A1 EP20728688.1A EP20728688A EP3973296A1 EP 3973296 A1 EP3973296 A1 EP 3973296A1 EP 20728688 A EP20728688 A EP 20728688A EP 3973296 A1 EP3973296 A1 EP 3973296A1
Authority
EP
European Patent Office
Prior art keywords
sample
protein
proteins
complement
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20728688.1A
Other languages
English (en)
French (fr)
Inventor
Sylvain Lehmann
Christophe HIRTZ
Jérôme VIALARET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spot To Lab
Universite de Montpellier I
Centre Hospitalier Universitaire de Montpellier CHUM
Original Assignee
Spot To Lab
Universite de Montpellier I
Centre Hospitalier Universitaire de Montpellier CHUM
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spot To Lab, Universite de Montpellier I, Centre Hospitalier Universitaire de Montpellier CHUM, Universite de Montpellier filed Critical Spot To Lab
Publication of EP3973296A1 publication Critical patent/EP3973296A1/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4044—Concentrating samples by chemical techniques; Digestion; Chemical decomposition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Definitions

  • the present application relates to a method of preparing a peptide sample from a biological sample. It also relates to a method for detecting and quantifying proteins using said method for preparing the peptide sample. Finally, it relates to the use of these methods for detecting or monitoring a condition or a disease.
  • the technical field of the invention is that of the biochemical analysis of proteins obtained from a biological sample.
  • the detection of protein clinical markers in a complex biological sample requires, for a proteomic analysis or by mass spectrometry, a first step of preparing a peptide sample, the quality of which is essential to then allow a sensitive and reproducible analysis. Indeed, the analysis of these media is subject to interference due to the presence of very predominant proteins and in certain cases to the release of the intracellular content during the preparation of the sample. This is particularly the case with blood products in which hemoglobin, albumin or immunoglobulins are very abundant.
  • WO 2014/118474 describes a method for determining the presence of prolidase for the detection of colorectal cancer, this method comprises a step of enzymatic digestion followed by a step of cleaning the proteins on a HLB solid phase support from Waters.
  • Yakundi et al. (Journal of Pharmaceutical and Biomedical analysis, 56, 1057-1063, 2011) cites a method for quantifying ranitidine in a dried blood sample, for clinical application. This method comprises a step of cleaning the proteins prior to an analysis by mass spectrometry, and does not include an enzymatic digestion step.
  • Rosting et al. ⁇ American Chemical Society, 87, 7918-24, 2015) discloses a method for detecting a model protein in a dried blood sample, comprising an enzymatic digestion step followed by pre-concentration by solid phase extraction (Solid- Extraction phase, or SPE), before analysis by mass spectrometry.
  • SPE Solid- Extraction phase
  • the inventors have now developed a method for the in vitro preparation of a sample of peptides, this method comprising successively steps of denaturation, reduction / alkylation, cleaning of the proteins by chromatography on a solid support comprising at least one polystyrene polymer. -divinyl benzene, then enzymatic digestion.
  • a method according to the invention allows the reproducible detection of a large number of clinical marker proteins from a small volume sample, this method can be applied successfully to a solid or liquid sample, such as plasma, and is automatable.
  • Analyzes of peptide samples by mass spectrometry have the advantage of absolute specificity in the detection of proteins and are considered to be standard methods.
  • a preparation method according to the invention, followed by an analysis by a method such as mass spectrometry for example makes it possible to have results statistically comparable to clinically validated tests, such as for example immunoassays.
  • a method according to the invention makes it possible to eliminate the interference due to the release of the intracellular content and to the presence of majority proteins, thus making it possible to improve the sensitivity, the specificity. and the analytical performance of the analysis of compounds.
  • a method for preparing a peptide sample according to the invention is suitable for the analysis of any type of biological sample, in particular blood samples, and more particularly solid blood samples, for which no reproducible and clinically validated method exists. 'is available today.
  • the use of a solid support of the blotter type is a recognized method of blood collection because it is non-invasive (finger tip sampling), easily transportable (in particular by post) and easy to implement; it can be carried out by the subject himself or by an unqualified person and is not dangerous, because the sample is decontaminated by drying.
  • a method according to the invention implemented on a sample on a solid support allows analysis at a lower cost, in particular for the longitudinal monitoring of subjects for multiple markers. Such a This approach is promising for monitoring populations whose access to analytical laboratories is restricted and for future developments in telemedicine.
  • the present application relates to a method for the in vitro preparation of a sample of peptides from a biological sample, comprising the following successive steps: a) denaturation of the proteins present in said sample, b) reduction and alkylation of the proteins from step a), c) cleaning of the proteins from step b) by reverse phase chromatography on a polymeric solid support, said solid support comprising at least one polystyrene-divinyl benzene polymer, and d) digestion by a protease of the proteins obtained from step c).
  • a method according to the invention comprises at least one step of cleaning the denatured, reduced and alkylated proteins and a step of enzymatic digestion, said step of cleaning the proteins taking place prior to the step of enzymatic digestion of said proteins.
  • biological sample is meant a sample comprising tissues and cells derived from the body, human or animal, and their derivatives, and in particular the following products: blood, serum, plasma, urine, stools, saliva, sputum, biopsies, and all body fluids and secretions.
  • the biological sample is a blood product in liquid form, chosen from: whole blood, serum and plasma
  • the biological sample is a blood product in solid or dried form, chosen from whole blood, serum and plasma.
  • the biological sample consists of dried whole blood deposited on a solid support, also called Dried Blood Spot (DBS).
  • DBS Dried Blood Spot
  • taking such a sample consists of depositing a drop of blood with a volume of 30 to 50 DL on a suitable solid support followed by a drying step.
  • the solid support for the sample is then easily handled and can in particular be sent by simple courier.
  • suitable solid supports there may be mentioned: blotting or collection papers such as "Whatman 903 paper” or "Ahlstrom TFN / 226 paper", on which blood can be deposited.
  • polystyrene-divinylbenzene polymer is meant a polymer comprising polystyrene crosslinked with divinylbenzene.
  • Polystyrene, or poly (1-phenylethylene) is obtained by polymerization of styrene monomer.
  • Divinylbenzene, or DVB is an aromatic hydrocarbon of formula C10Hio used as a crosslinking agent.
  • a solid support for cleaning proteins comprises at least one polystyrene-divinyl benzene polymer optionally associated with another polymer or with any other suitable element.
  • the solid support of the reverse phase chromatography step is characterized by the presence of polystyrene-divinyl benzene polymer beads, the size of which is between 10 and 50 mm, preferably between 20 and 40 mm and preferably 30 m. , on the one hand, and pores whose size is between 500 and 10,000 Angstroms, and preferably between 2,000 and 4,000 Angstroms, on the other hand.
  • solid supports comprising at least one polystyrene-divinyl benzene polymer which can be used in a process according to the invention
  • solid supports comprising at least one polystyrene-divinyl benzene polymer which can be used in a process according to the invention
  • RP-W® cartridges sold by the company Agilent.
  • Said RP-W® cartridges are described for use in a method and an application very different from that of the method according to the invention. Indeed, the methods of the state of the art typically describe the use of these cartridges during the production of recombinant antibodies, for a “desalination” step, that is to say in particular to ensure the elimination of the 6M guanidine necessary for the denaturation of the antibodies, prior to the digestion of the latter with trypsin.
  • each of the steps of denaturation, reduction, alkylation and enzymatic digestion of proteins is carried out by means of any method well known to those skilled in the art, under conditions of buffer, concentration, temperature and duration. appropriate.
  • the denaturation is carried out thanks to the addition of a protein denaturing agent, for example 8M urea
  • the reduction is carried out thanks to the addition of an agent capable of reducing the disulfide bonds of proteins, for example DTT
  • the alkylation of the cysteines released during the reduction is carried out by the addition of an alkylating agent, for example iodoacetic acid (IAA) .
  • an alkylating agent for example iodoacetic acid (IAA)
  • the enzymatic digestion of the proteins is preferably carried out by the addition of at least one protease chosen from: trypsin, endoproteinase GluC and endoproteinase LysC. According to a particular aspect of a process according to the invention, the enzymatic digestion is carried out for a duration greater than 2 hours, preferably greater than or equal to 10 hours, preferably greater than or equal to 14 hours, preferably equal to 14 hours. .
  • the enzymatic digestion is carried out in the presence of a ratio between the quantity of enzyme present and the quantity of substrate protein of between 1/10 and 1/200 and preferably between 1 / 50 and 1/100.
  • a ratio between the quantity of enzyme present and the quantity of substrate protein of between 1/10 and 1/200 and preferably between 1 / 50 and 1/100.
  • the present application relates to a method for the in vitro preparation of a sample of peptides from a blood sample in solid or dried form, said method comprising a step of extracting proteins from said solid blood sample prior to the denaturation, reduction and alkylation, protein cleaning and protease digestion steps.
  • the extraction of the proteins is carried out by any extraction method known to a person skilled in the art, in particular by placing the sample in the presence of ammonium bicarbonate at room temperature, optionally in the presence of ovalbumin.
  • the present application relates to a method for detecting the presence of at least one protein considered as a clinical marker in a biological sample, said detection method comprising an in vitro method for preparing a peptide sample, according to the invention, followed by a step of detecting the presence of at least one protein in said sample.
  • the present application relates to a method for detecting and quantifying at least one protein in a biological sample, said method for detecting and quantifying comprising an in vitro process for preparing a peptide sample, according to the invention, followed by a step of detecting and quantifying at least one protein in said sample.
  • the detection and / or quantification of said at least one protein is carried out by any known technical means, preferably by mass spectrometry, more preferably by mass spectrometry coupled to liquid chromatography, or Liquid Chromatography - Mass Spectrometry (LC-MS ). Said detection and / or quantification step can be implemented for one, two or more proteins. Said mass spectrometry can be carried out in a multiplex form.
  • Detection and quantification of proteins in a complex biological sample by LC-MS typically includes preparation of a peptide sample, followed by liquid chromatographic separation of said peptide sample, followed by mass spectrometry analysis, with l identification followed optionally by protein quantification, then statistical analysis of the results.
  • the detection and / or quantification of proteins is carried out using at least one standard consisting of a labeled or unlabeled peptide, making it possible to detect the corresponding specific protein.
  • Said standards are well known to those skilled in the art who can easily choose them from the available commercial standards, depending on the nature of the protein (s) of interest.
  • the subject of the present invention is a method for detecting, optionally followed by quantification, of at least one protein chosen from the group consisting of the following proteins: afamine, alpha-1-antichymotrypsin, alpha- lB-glycoprotein (A1BG), alpha 1 acid glycoprotein, albumin (ALBU), alpha-2-HS-glycoprotein, alpha-2- antiplasmin, alpha-2-macroglobulin (A2MG), antithrombin-3 (ANT3), apolipoprotein B100 ( Apo B100), apolipoprotein C2 (Apo C2), apolipoprotein D, apolipoprotein E (Apo E), apolipoprotein M, apolipoprotein (a), apolipoprotein al (Apo Al), Apolipoprotein A2 (Apo A2), apolipoprotein A2 (Apeta A2), apolipoprotein 2-4 glycoprotein 1, beta-2
  • the subject of the present invention is a method of detection, optionally followed by quantification, of one, two, three, four, five, six, seven, eight, nine, ten, fifteen, twenty , twenty-five, thirty, thirty-five, forty or more than forty proteins selected from the group defined above.
  • the present application relates to a kit suitable for the in vitro preparation of a sample of peptides from a biological sample according to the invention, said kit comprising at least:
  • solid support comprising at least one polymer chosen from the family of polystyrene-divinyl benzene polymers.
  • Said reagents are chosen from existing reagents, well known to those skilled in the art.
  • the present application relates to the use of a method for the in vitro preparation of a sample of peptides from a biological sample according to the invention.
  • the present application relates to the use of a method for detecting and potentially quantifying at least one protein in a biological sample, according to the invention.
  • the present invention relates to the use of a method for the in vitro preparation of a sample of peptides from a biological sample, according to the invention, and / or the use of a detection and potentially quantification method according to the invention, for the detection and potentially quantification of at least one protein chosen from the group consisting of the following proteins: afamine, alpha-1-antichymotrypsin, alpha-1B- glycoprotein (A1BG), alpha 1 acid glycoprotein, albumin (ALBU), alpha-2-HS-glycoprotein, alpha-2-antiplasmin, alpha-2-macroglobulin (A2MG), antithrombin-3 (ANT3), apolipoprotein B100 (Apo B100 ), apolipoprotein C2 (Apo C2), apolipoprotein D, apolipoprotein E (Apo E), apolipoprotein M, apolipoprotein (a), apolipoprotein al (Apo Al),
  • the present invention relates to the use of a method for the in vitro preparation of a sample of peptides from a biological sample, according to the invention, and / or the use of a detection and potentially quantification method according to the invention, for the detection and potentially of quantification of one, two, three, four, five, six, seven, eight, nine, ten, fifteen, twenty, twenty -five, thirty, thirty-five, forty or more than forty proteins selected from the group defined above.
  • the present application relates to the use of a method for the in vitro preparation of a sample of peptides from a biological sample according to the invention for the detection and / or monitoring of a condition. or a particular disease chosen from:
  • the detection and / or the monitoring of a disease or a particular condition can be carried out by the detection and / or the quantification of at least one protein considered as a clinical marker, possibly associated with the detection and / or the quantification at least one non-protein clinical marker.
  • the present application relates to the use of a method for the in vitro preparation of a sample of peptides from a biological sample, according to the invention, for the detection and / or monitoring.
  • the state of health, nutritional and frailty and of a subject in particular an elderly subject.
  • elderly subject is meant a subject of 75 years or more, more particularly a subject of 85 years or more.
  • a use according to the invention comprises the detection and / or the quantification of one or more proteins chosen from: albumin, alpha 1 acid glycoprotein, transthyretin and CRP (C Reactive Protein).
  • FIG. l schematically represents an embodiment of a method for preparing a peptide sample according to the invention and from a DBS sample (FIG. 1A) and an embodiment of a method for preparing a. peptide sample according to the state of the art from plasma (FIG. IB).
  • FIG. 2 represents a histogram showing the compared results of the LC-MS analysis of 26 different proteins, carried out on samples prepared according to three different protocols: a) method according to the invention applied to a dried blood sample (“DBS RPW” ), b) method according to the invention applied to a plasma sample (“plasma”), c) method for preparing DBS samples according to the state of the art (“DBS preparation standard”).
  • DBS preparation standard For each of the proteins, the values of the areas obtained during the analysis by mass spectrometry under the conditions "DBS RPW" and "plasma” are divided, respectively, by the corresponding values of the areas obtained with the standard method for preparing the protein. 'sample.
  • C reactive protein CRP
  • serotransferrin Fig. 3B
  • EXAMPLE 1 Preparation of a peptide sample from a dried blood sample (DBS) and comparative analysis by LC-MS.
  • the efficiency of the method according to the invention was evaluated by detecting and quantifying 26 proteins in LC / MS, by respectively comparing the analysis of a DBS sample treated by a method according to the invention (“DBS-RPW”) and the analysis of a plasma sample treated by a method according to the state of the art (“plasma”) to an analysis carried out directly from a DBS sample (“DBS standard”).
  • DBS-RPW analysis of a DBS sample treated by a method according to the invention
  • plasma plasma sample treated by a method according to the state of the art
  • FIG. I B The steps of the method according to the invention are shown diagrammatically in FIG. 1A, the steps of the method for preparing a sample from plasma and according to a method of the state of the art are diagrammed in FIG. I B.
  • the experiment was performed in duplicate and each LC / MS analysis was performed in duplicate.
  • the 26 proteins are as follows: A1 BG, A2MG, ANT3, Apo Al, Apo A2, Apo B100, Apo C2, Apo E, B2M, CERU, CF_X, C2, C3, C4B, CRP, CysC, FIBA, H PT, FIBB, IGFB3, PLMN, ORM, RET4, TRANSF, TTHY, ALBU.
  • DBS-RPW The preparation process from a DBS sample according to the invention “DBS-RPW” is carried out as follows.
  • a “DBS punch” is produced by punching the solid support (type 226 blotting paper) containing the sample. Said punch is transferred to a plate
  • the proteins are extracted by adding 200 m ⁇ - of 50 mM ammonium bicarbonate, then stirring for 30 minutes using a shaker. bench at 350 rpm on an Eppendorf® Thermomixer Compact device.
  • the sample is then denatured by adding 200 ml of 8M urea and stirring again for 10 minutes.
  • the disulfide bonds of the proteins in the sample are then reduced by adding 21 m ⁇ - of 200 mM DTT in 1 M tris pH 8.5, and 12 pL 1 M tris pH 8.5, and stirring for one hour at 37 ° C. with stirring at 350 rpm on an Eppendorf® Thermomixer Compact.
  • the liberated cysteines are then alkylated by adding 18 m ⁇ - of 1 M IAA, 6 ⁇ l of 1 M Tris pH 10, and further stirring for 30 minutes at 37 ° C.
  • the alkylation step is stopped by adding 20 m ⁇ - of 200 mM DTT.
  • the sample is then acidified by adding 10 m ⁇ - of formic acid before transferring the 210 m ⁇ - of the supernatant into two new wells.
  • the sample cleaning step is then carried out on RP-W® cartridges sold by the company Agilent.
  • the cartridges are washed and conditioned with 100 ⁇ L at 300 ⁇ L / min of a solution of acetonitrile (70%) / TFA (0.1%) / water (29.9%), and are equilibrated with 50 ⁇ L at 10 pL / min of a solution of 0.1% formic acid.
  • the sample is loaded onto an RP-W cartridge (Cat # G5496-60086) at 5 pL / min.
  • the RP-W phase contained in the cartridge is washed with 50 m ⁇ - at 10 m ⁇ / Gh ⁇ h of a 0.1% TFA solution and then the cleaned sample is eluted from the cartridge with 20 m ⁇ - at 5 pL / min of a solution of acetonitrile (70%) / formic acid (0.1%) / water (29.9%).
  • the elution is put to dryness (Speedvac TM).
  • the dry sample is resuspended in 37.4 ⁇ L of 20 mM Tris pH 8.5; 5.6 ⁇ g of trypsin / LysC are added to carry out the tryptic digestion. This reaction lasts 14 hours at 37 ° C.
  • the preparation of the “standard DBS” samples is carried out as follows: one or two drops of capillary blood, obtained after pricking the fingertip with a lancet, are deposited on each spot of DBS. It is also possible to deposit with the use of a pipette 70 ⁇ L of venous whole blood collected in a tube on a DBS spot. After deposit, the cards are left to dry for 2 hours at room temperature. They are put in an individual plastic bag and can be stored according to use at room temperature, at 4 ° C or frozen (-20 ° C or -80 ° C). Before analysis, the cards are returned at room temperature. A 6 mm diameter punch is then taken for each spot and transferred into a 2 ml Eppendorf LoBind tube.
  • the preparation of the "plasma” samples is carried out as follows: the process is shown diagrammatically in FIG. IB, it represents a typical process known in the state of the art and comprises the following stages: starting from 2 ⁇ L of liquid or deposited plasma on a “Whatman 903 paper” or “Ahlstrom FN / 226 paper” support, the proteins are denatured and reduced, then undergo an alkylation, an enzymatic digestion (in the presence of trypsin / LysC for 14 h at 37 ° C), then a step of cleaning the peptides obtained carried out on a ZORBAX Eclipse Plus C18 type column, followed by analysis by LC-MS.
  • the intensities in mass spectrometry found after treatment of the DBS sample by a method according to the invention are 19 times more intense than those obtained directly after standard DBS. These intensities correspond for the majority of proteins to those obtained on a sample of plasma prepared by a standard method.
  • the median of the overall CV obtained this time on the plasma collected from the patients at the same time as the DBS was 6.7% with a range CVs that ranged from 2 to 48%.
  • a correlation between the values obtained in the plasma (those which are therefore used for clinical purposes) and those obtained in the DBS was calculated. 35 peptides show a very strong correlation between “standard plasma” and “DBS-RPW” (correlation coefficient> 0.8), 32 an intermediate correlation (between 0.6 and 0.8) and 24 a weak correlation ( ⁇ 0.6 ).
  • the plasmas of 95 different patients, recruited in chronological order and without any particular pathology were analyzed, on the one hand, by mass spectrometry on samples prepared by a method according to the invention and in parallel by immunoassay, on a COBAS 6000 automaton. (Roche Diagnostic) on the Biochemistry site of the adjoin hospital. The results obtained are shown in figure 3, together with the analysis of CRP (figure 3A) and serotransferrin (figure 3B) respectively. The results obtained by the two methods were compared by software R. The comparison shows a statistically significant correlation for each of the two quantified proteins.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
EP20728688.1A 2019-05-20 2020-05-19 Verfahren zur herstellung einer peptidprobe Pending EP3973296A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1905247A FR3096459B1 (fr) 2019-05-20 2019-05-20 Procédé de préparation d’un échantillon peptidique
PCT/EP2020/063944 WO2020234287A1 (fr) 2019-05-20 2020-05-19 Procédé de préparation d'un échantillon peptidique

Publications (1)

Publication Number Publication Date
EP3973296A1 true EP3973296A1 (de) 2022-03-30

Family

ID=67957056

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20728688.1A Pending EP3973296A1 (de) 2019-05-20 2020-05-19 Verfahren zur herstellung einer peptidprobe

Country Status (6)

Country Link
US (1) US20220196524A1 (de)
EP (1) EP3973296A1 (de)
JP (1) JP2022533431A (de)
CA (1) CA3140439A1 (de)
FR (1) FR3096459B1 (de)
WO (1) WO2020234287A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3001805B1 (fr) 2013-02-01 2015-02-20 Biomerieux Sa Procede de detection d'un cancer colorectal
MX2018009339A (es) * 2016-02-04 2019-01-10 Oncobiologics Inc Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas.
EP3662287B1 (de) * 2017-08-01 2024-02-28 Amgen Inc. Systeme und verfahren zur echtzeit probenvorbereitung von polypetides zur analyse mittels massenspektrometrie

Also Published As

Publication number Publication date
FR3096459A1 (fr) 2020-11-27
US20220196524A1 (en) 2022-06-23
CA3140439A1 (fr) 2020-11-26
WO2020234287A1 (fr) 2020-11-26
JP2022533431A (ja) 2022-07-22
FR3096459B1 (fr) 2024-03-08

Similar Documents

Publication Publication Date Title
Ono et al. Increased serum levels of advanced glycation end-products and diabetic complications
Scheijen et al. l (+) and d (−) lactate are increased in plasma and urine samples of type 2 diabetes as measured by a simultaneous quantification of l (+) and d (−) lactate by reversed‐phase liquid chromatography tandem mass spectrometry
Zuo et al. Determination of creatinine, uric and ascorbic acid in bovine milk and orange juice by hydrophilic interaction HPLC
Tarnow et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes
Yanagisawa et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients
Miyata et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?
Scheijen et al. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection
Kiernan et al. Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay
EP2223120A1 (de) Nichtinvasives verfahren zur sammlung biologischer daten zwecks erstellung einer diagnose über eine hautkrankheit
EP3394622B1 (de) Reagenzverdünnungsmittel
Carter et al. Validation of a metabolite panel for early diagnosis of type 2 diabetes
EP3384047A1 (de) Verfahren zur bewertung des komplikationsrisikos bei patienten mit systemischem inflammatorischem response-syndrom (sirs)
EP1977244B1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
EP3973296A1 (de) Verfahren zur herstellung einer peptidprobe
Falk et al. An automated method for the determination of sulfonamides in plasma
CN114026427A (zh) 诊断肾病的标志物以及诊断方法
WO2009115756A2 (fr) Procede de detection directe de l'albumine modifiee de l'ischemie par utilisation d'un partenaire de liaison a un derive aldehyde issu de la peroxydation de lipides sous forme liee
FR3002044A1 (fr) Marqueur dyrk1a pour la maladie d'alzheimer
FR3048780A1 (fr) Procede de diagnostic in vitro d'atteintes hepatiques
JP3615428B2 (ja) 蛋白結合型糖化蛋白を酵素免疫法で測定するための前処理方法
Van Merris et al. Simple quantification of endogenous retinoids in bovine serum by high-performance liquid chromatography–diode-array detection
US20220057392A1 (en) Methods and compositions for exosome-based diagnostics and diagnosis of disease
EP1542017A1 (de) Verfahren zum untersuchen und diagnostizieren des integrationsfehlfunktionssyndroms
JP7390229B2 (ja) 生体試料の分析方法及びミトコンドリアの機能の評価方法
JP2004163379A (ja) 糖尿病の診断方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230707

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SPOT TO LAB

Owner name: UNIVERSITE DE MONTPELLIER

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER